AnaptysBio Inc (ANAB)
21.32
+0.16
(+0.73%)
USD |
NASDAQ |
Nov 22, 10:43
AnaptysBio Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
September 30, 2024 | 0.00 |
June 30, 2024 | 0.00 |
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.0034 |
Date | Value |
---|---|
September 30, 2019 | 0.0073 |
June 30, 2019 | 0.0107 |
March 31, 2019 | 0.0139 |
December 31, 2018 | 0.0156 |
September 30, 2018 | 0.0198 |
June 30, 2018 | 0.0408 |
March 31, 2018 | 0.0453 |
December 31, 2017 | 0.0469 |
September 30, 2017 | 0.1408 |
June 30, 2017 | 0.1293 |
March 31, 2017 | 0.1268 |
December 31, 2016 | 0.3517 |
September 30, 2016 | 0.1113 |
June 30, 2016 | 0.1116 |
March 31, 2016 | 0.1179 |
December 31, 2015 | 0.1158 |
September 30, 2015 | 0.107 |
June 30, 2015 | 0.8283 |
March 31, 2015 | |
December 31, 2014 | 0.7998 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2020
0.0034
Maximum
Dec 2019
0.0002
Average
--
Median
Mar 2020
Debt to Equity Ratio Benchmarks
Eli Lilly and Co | 2.185 |
Regeneron Pharmaceuticals Inc | 0.0677 |
Ligand Pharmaceuticals Inc | 0.00 |
Agios Pharmaceuticals Inc | 0.00 |
ADMA Biologics Inc | 0.437 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 493.42M |
Total Liabilities (Quarterly) | 409.05M |
Shareholders Equity (Quarterly) | 84.37M |
Current Ratio | 10.23 |